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Bad Habits, and Chronic Disease
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Department of Neurobiology, Yale School of Medicine, New Haven, Connecticut
our brain is sensitive to stress. Both acute and chronic stress cause cognitive deficits and
induce chronic disorders such as drug addiction. In a June 2011 conference at Yale entitled
“The Science of Stress: Focus on the Brain, Breaking Bad Habits, and Chronic Disease,”
Drs. Amy Arnsten and Sherry Mckee discussed the roles of prefrontal cortex in the treatment
of stress impairments and addiction. Medications to strengthen the prefrontal function, such
as prazosin and guanfacine, may reduce the harm of stress and help overcome smoking and
alcohol abuse. 
Stress-associated disorders are preva-
lent in our modern society. Many chronic
diseases  are  induced  or  exaggerated  by
stress, such as cardiovascular disease, can-
cer, and depression [1]. A recent Yale Con-
tinuing  Medical  Education  (CME†)
conference in June 2011 entitled “The Sci-
ence of Stress: Focus on the Brain, Break-
ing Bad Habits, and Chronic Disease” drew
attention to new advances in neurobiologi-
cal  research  on  mechanisms  underlying
stress effects and proposed potential clini-
cal treatments of stress-related chronic dis-
eases. 
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sor of Neurobiology, and Dr. Sherry McKee,
Associate Professor of Psychiatry and Di-
rector  of  Yale  Behavioral  Pharmacology
Laboratory, focused on the neurobiology of
the prefrontal cortex (PFC) during stress.
Their findings suggest that molecular mod-
ulations  that  strengthen  PFC  can  rescue
stress-induced cognitive deficits and thus
allow subjects to overcome addictive be-
haviors. 
Dr. Arnsten first introduced the functions
of the PFC, which underlies our most ad-
vanced  cognitive  abilities,  guiding  our
thoughts, actions, and emotions using work-
ing memory [2]. In alert, non-stressful condi-
tions,  the  PFC  exerts  top-down  cognitive
control on other cortical regions and subcorti-
cal areas to locate attention, inhibit inappro-
priate  actions,  and  regulate  emotions.
However, the PFC is the brain region that is
most sensitive to the detrimental effects of
stress exposure. During stressful conditions,
the amygdala activates stress pathways in the
hypothalamus and brainstem, which evoke
high  levels  of  norepinephrine  (NE)  and
dopamine (DA) release. This impairs PFC
function but strengthens amygdala function
[2]. The amygdala performs a primary role in
the processing and memory of emotional re-
actions. Thus, during stress, there is a switch
from slow, thoughtful PFC regulation to the
reflexive and rapid emotional responses of the
amygdala and related subcortical structures. 
In the past decades, the Arnsten lab
aimed to identify the molecular mechanisms
underlying stress-induced PFC impairment.
They utilized in vivo electrophysiological
recordings  in  monkey  dorsolateral  PFC
when the animal was doing a working mem-
ory task (an oculomotor delayed response
task, which requires the monkey to remem-
ber the location of a spatial cue and make
eye movement to that location after a delay
period). They could also apply drugs target-
ing different molecules simultaneously dur-
ing recording by iontophoresis (a technique
using small electric charge to deliver drugs
to a restricted region) so they could test the
functions of particular molecules in an ac-
tive network.
Two of the molecules identified that are
very important for PFC function are ʱ1-
adrenergic receptors and ʱ2A-adrenergic re-
ceptors. The ʱ2A receptors are Gi protein
coupled receptors. When activated, they will
inactivate adenyl cyclase, resulting in a re-
duction  of  intracellular  cyclic  adenosine
monophosphate (cAMP). The ʱ1 receptors
are Gq protein-coupled receptors. Upon ac-
tivation, they will activate phospholipase C
(PLC), which leads to an increase in inositol
trisphosphate (IP3) and calcium. This acti-
vates an enzyme called protein kinase C
(PKC), which can phosphorylate many other
molecules and trigger downstream effects. 
They found that excessive amounts of
NE during stress reduces PFC function by
activating ʱ1-adrenergic receptors. ʱ1 ago-
nists ― phenylephrine and cirazoline ― re-
duced PFC firing at the cellular level and
impaired working memory behaviorally. To
test the downstream of ʱ1 receptor activa-
tion, they conducted co-iontophoresis of the
PKC inhibitor chelerythrine and found it
could reverse the phenylephrine-induced re-
duction in PFC neuronal firing [5]. Also,
prazosin, an ʱ1 antagonist, rescued the ago-
nist-induced PFC loss-of-function [3,4]. Dr.
Arnsten thus proposed that excessive NE re-
lease during stress would activate ʱ1-adren-
ergic  receptors  and  downstream  PKC
signaling, leading to weakened PFC func-
tion.
In comparison to the stressed condition,
during alert, non-stressful conditions, mod-
erate  amounts  of  NE  can  activate  ʱ2A-
adrenergic  receptors  and  strengthen  PFC
function. ʱ2A receptor activation reduces
the level of cAMP and closes cAMP-gated
hyperpolarizing ion channels on the den-
dritic spines, thus increasing synaptic effi-
cacy. This leads to stronger PFC network
activity [4]. They found that guanfacine, an
ʱ2A agonist, increased PFC neuronal firing
and improved working memory perform-
ance. Also, guanfacine decreases impulsive
responding on a delay discounting task (an-
imals are able to inhibit an impulsive re-
sponse to a small, immediate reward and
wait for a larger reward) [6,7]. Thus, the ac-
tivation of ʱ2A receptors enables the animal
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ive actions. Guanfacine also can protect the
animals  from  chronic  stress.  It  has  been
shown that chronic stress harms PFC cogni-
tive function and causes PFC grey matter
loss [8]. Daily guanfacine treatment could
protect prefrontal grey matter loss and cog-
nitive performances from chronic stress in
rats. 
In  the  second  part  of  the  talk,  Dr.
McKee introduced the clinical applications
of these molecular targets in stress-induced
addictions. Stress is a primary mechanism
involved in the maintenance of ― and re-
lapse to ― tobacco dependence and alcohol
use [9]. It has been known that stress re-
duces PFC grey matter and impairs the top-
down  rational  control  by  PFC.  Higher
cumulative adverse life events is associated
with  lower  mean  grey  matter  volume  of
PFC, according to McKee. Will prazosin (ʱ1
antagonist) or guanfacine (ʱ2A agonist) im-
prove stress reactivity and decrease addic-
tive behaviors in humans by strengthening
the PFC function?
Studies  have  shown  that  these  two
drugs do help overcome stress disorders and
drug-taking habits. Prazosin reduces night-
mares and clinical signs of patients with
post-traumatic stress disorders (PTSD) [10].
Prazosin also decreases stress-induced alco-
hol craving, anxiety, and negative emotions
in the laboratory [11]. Similarly, guanfacine
has been shown to reduce stress reactivity,
improve cognitive control, and decrease cig-
arette use in smokers [11]. Compared to an-
other ʱ2 agonist, clonidine, which is tested
to reduce tobacco craving, guanfacine has a
better side-effect profile, according to Dr.
McKee. 
Dr. McKee and colleagues conducted a
study to test the drug effect on stress-in-
duced  smoking  relapse  by  administering
guanfacine  or  placebo  daily  to  smokers.
They found that stress reduced the ability to
resist smoking in the placebo group, and this
effect was attenuated by guanfacine. Stress
also  increased  the  number  of  cigarettes
smoked in the placebo group, and the in-
crease was attenuated by guanfacine. Guan-
facine was able to reduce the stress-induced
tobacco craving as well. A functional mag-
netic resonance imaging (fMRI) study com-
paring the placebo and guanfacine group
showed increased activation in the anterior
cingulate, ventromedial prefrontal cortex,
and bilateral insula in the guanfacine group
during the incongruent versus the congruent
stimuli in a stroop task (e.g., an incongruent
stimuli means that the word “red” printed in
blue ink instead of red ink, and subjects
needed  to  name  the  actual  color  of  the
word). During the 4-week treatment period,
guanfacine significantly reduced cigarettes
per  day  and  improved  retention,  McKee
said.
Thus, from basic mechanism research
to clinical application, both prazosin and
guanfacine  demonstrate  promise  for  the
treatment of stress-induced alcohol and to-
bacco dependence. The medications to res-
cue prefrontal function thus show potential
to rescue stress impairments and help over-
come bad habits. 
More  pharmaceutical  targets  are  ex-
pected to be identified to reduce the harm of
stress and hopefully for other psychiatric
disorders, such as schizophrenia and de-
pression. However, there are still hurdles to
overcome in this field. A sound understand-
ing of the brain circuits involved in those
disorders is a requirement. Knowledge of
the neurochemical needs of those circuits
and, if possible, the neurochemical changes
in those circuits associated with the symp-
tom is needed. However, the neurophysio-
logical  substrates  of  most  psychiatric
disorders are still poorly understood. People
have known that the PFC is sensitive to
stress and is impaired in many psychiatric
disorders. Revealing the cellular and molec-
ular mechanisms within the PFC is poten-
tially helpful for developing effective drugs
to treat the diseases. 
There is also difficulty in the translation
from basic research to human therapies. A
great challenge in drug development is that
the mechanisms identified in model organ-
isms (usually mice and rats) might be dif-
ferent from those at work in a human being.
Studies in non-human primates can be par-
ticularly advantageous in this regard. Be-
481 Jin: Reducing the harm of stresscause they are more similar to us evolution-
arily, a drug that succeeds in non-human pri-
mates  has  a  high  possibility  to  work  in
humans. In fact, the exact same doses of
guanfacine and prazosin that have improved
cognitive functions in young monkeys are
now used in humans [12].
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